Evolve Private Wealth’s Bio-Rad Laboratories Class A BIO Stock Holding History

Evolve Private Wealth’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$261K	Buy	+890	New	+$252K	0.02%	798

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Evolve Private Wealth's BIO Position: Q2 2026 in Review

Evolve Private Wealth opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 890 shares worth $261K. The stake represents 0.02% of the portfolio and ranks #798 among its holdings.

397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Evolve Private Wealth held 890 shares of Bio-Rad Laboratories Class A worth $261K as of Q2 2026.
Bio-Rad Laboratories Class A was a new Evolve Private Wealth position in Q2 2026.
Bio-Rad Laboratories Class A made up 0.02% of Evolve Private Wealth's portfolio in Q2 2026, its #798 holding.
397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.